Latest Hospitality News

EMVision Medical Devices has activated two additional key sites in its pivotal trial for the emu™ bedside brain scanner, advancing its path toward FDA clearance. These new sites join a growing network of leading stroke centres across the US and Australia.

ReNerve Limited has entered a strategic partnership with Berkeley Biologics to develop and commercialise two new tissue-based product ranges, aiming to expand its footprint in the US surgical market by the end of 2025.

Austco Healthcare has completed its strategic acquisition of New Zealand’s G&S Technologies, enhancing its healthcare communication offerings and direct sales reach in the region.

Beamtree Holdings has forged a strategic alliance with the NHS Confederation to launch a pioneering healthcare analytics platform across UK NHS Trusts, marking a significant step in its international expansion.

HealthCo Healthcare & Wellness REIT and its partners have arranged a short-term partial rent deferral with Healthscope’s receivers to maintain hospital operations during a critical transition period.

Xamble Group has acquired a 19% stake in Malaysia’s leading loyalty platform B Infinite, aiming to deepen influencer marketing engagement and unlock new revenue streams across Southeast Asia.

Aroa Biosurgery has reported FY25 results that exceed revenue guidance and deliver a positive normalised EBITDA, setting the stage for ambitious growth and reimbursement expansion in FY26.

Fisher & Paykel Healthcare has reported a record full-year revenue of NZ$2.02 billion for FY2025, alongside a 43% increase in underlying net profit after tax. The company also raised its dividend, reflecting strong operational performance and strategic investments.

Smartpay Holdings Limited posted solid FY25 financials with revenue surpassing $104 million, driven by Australian market gains and promising New Zealand pilot progress. The company is advancing its trans-Tasman payments strategy amid regulatory developments.

OncoSil Medical has secured $8.7 million through a placement and share purchase plan to fund commercialization of its pancreatic cancer treatment device, aiming for positive cash flow by mid-2026. Near-completion clinical trials could soon unlock broader market access.

4DMedical has submitted its CT:VQ™ software to the FDA, aiming to revolutionize lung ventilation and perfusion imaging by replacing traditional nuclear scans with a non-contrast CT-based solution.

Proteomics International has validated its PromarkerEndo blood test as a highly accurate, non-invasive diagnostic tool for endometriosis, with commercial launch planned in Australia for Q3 2025. The test promises to reduce the average seven-year diagnostic delay by providing a simple risk score applicable across all disease stages.